Treadmill stress echocardiography (TSE) reveals hidden physiologic limitations in patients with asymptomatic hypertrophic cardiomyopathy (HCM), aiding in diagnosis and prognosis. Many patients with ...
A statistically significant reduction from baseline in Valsalva LVOT gradient was observed with mavacamten vs placebo at week 28. Topline data were announced from a phase 3 trial evaluating mavacamten ...
EXPLORER-CN data presented in oral late-breaking science session at ESC 2023 Data from the trial published simultaneously in JAMA Cardiology Mavacamten demonstrated improvement in Valsalva LVOT peak ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating ...
Credit: Getty Images HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C. Hypertrophic cardiomyopathy (HCM) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results